On December 1, 2016, the Company received a decision letter from NASDAQs Office of General Counsel stating that the Hearings Panel has granted the Companys request and, accordingly, the Companys common stock will continue to trade on the NASDAQ Stock Market provided that the Company becomes current in its periodic filings with the SEC on or before March 10, 2017. The letter stated that March 10, 2017 represents the full extent of the Hearing Panels discretion to grant continued listing while the Company is non-compliant. The Company is continuing to work diligently to complete its previously announced accounting reviews, restatement of prior period financial statements, transition to a new independent registered public accounting firm and 2015 audit so that it will be in a position to file its delinquent periodic reports with the SEC as soon as possible. However, there can be no assurance that the Company will be able to complete all of this work and become current in its SEC filings by March 10, 2017. If the Company is not able to file all of its delinquent periodic reports with the SEC by March 10, 2017, then the Hearings Panel will issue a final delist determination and the Company will be suspended from trading on the NASDAQ Stock Market. There can be no assurance regarding the timing or ultimate outcome of this process or the ability of the Company to successfully maintain its NASDAQ listing. About Osiris Therapeutics Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4, Cartiform, Grafix, TruSkin and Stravix. Osiris, Grafix, and Cartiform are registered trademarks of Osiris Therapeutics, Inc.; TruSkin and Stravix are trademarks of Osiris Therapeutics, Inc.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/osiris-provides-regarding-nasdaq-listing-220000902.html
(KTTC) – Students from Rochester Community and Technical College showed off their horsebackriding skills during anend-of-the-semester horse showMonday afternoon. http://christianrichardsonplus.accessnetwork.us/2016/09/06/a-detailed-look-at-rapid-solutions-of-vocationRCTC’S Equine Science Programhosted the eventat the Silver Springs Equestrian Center in Elgin. “You feel very free. But yet you’re still in control,” said rider Megan Anderson.”Imagine like thinking you’re flying. That’s the majority of what it feels like. It feels like you’re flying.” check this site outA judge scored the students on a variety of skills, such ashow well theymaintained their form during theirjumps. “They shouldn’t be looking down. They should be looking where they’re going,” said Julie Christie, an instructor with the RCTC’s Equine Science Program.”Do they ride their horses in a straight line, get their horses to the base of the jump in a nice way, or do they totally lack control and have reins that are too long?” Other techniques the students have learned were also put to the test. “They’re going to do several undersaddle classes, which are what we call rail classes.
For the original version including any supplementary images or video, visit http://www.kttc.com/story/33918964/2016/12/05/it-feels-like-youre-flying-rctc-students-demonstrate-horseback-riding-skills